BRPI0710912A2 - biomarcadores para proliferação endometrial - Google Patents

biomarcadores para proliferação endometrial Download PDF

Info

Publication number
BRPI0710912A2
BRPI0710912A2 BRPI0710912-1A BRPI0710912A BRPI0710912A2 BR PI0710912 A2 BRPI0710912 A2 BR PI0710912A2 BR PI0710912 A BRPI0710912 A BR PI0710912A BR PI0710912 A2 BRPI0710912 A2 BR PI0710912A2
Authority
BR
Brazil
Prior art keywords
endometrial proliferation
biomarkers
relates
endometrial
proliferation
Prior art date
Application number
BRPI0710912-1A
Other languages
English (en)
Inventor
Bobadilla Maria
Chibout Salah-Dine
Cordier André
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0710912A2 publication Critical patent/BRPI0710912A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)

Abstract

BIOMARCADORES PARA PROLIFERAçãO ENDOMETRIAL. A presente invenção refere-se a um processo para a determinação qualitativa e/ou quantitativa da proliferação endometrial em uma amostra. A presente invenção refere-se ainda a composições ou kits e arranjos para a determinação qualitativa e/ou quantitativa da proliferação endometrial. Além disso, a invenção refere-se a um processo para o diagnóstico de um distúrbio que está associado com uma disfunção de proliferação endometrial ou uma pré-disposição para a mesma em um indivíduo.
BRPI0710912-1A 2006-04-28 2007-04-26 biomarcadores para proliferação endometrial BRPI0710912A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0608483.4A GB0608483D0 (en) 2006-04-28 2006-04-28 Biomarkers for endometrial proliferation
GB0608483.4 2006-04-28
PCT/EP2007/003694 WO2007128429A1 (en) 2006-04-28 2007-04-26 Biomarkers for endometrial proliferation

Publications (1)

Publication Number Publication Date
BRPI0710912A2 true BRPI0710912A2 (pt) 2012-02-22

Family

ID=36590031

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0710912-1A BRPI0710912A2 (pt) 2006-04-28 2007-04-26 biomarcadores para proliferação endometrial

Country Status (10)

Country Link
EP (1) EP2016417A1 (pt)
JP (1) JP2009535023A (pt)
KR (1) KR20090009212A (pt)
CN (1) CN101427139A (pt)
AU (1) AU2007247497A1 (pt)
BR (1) BRPI0710912A2 (pt)
CA (1) CA2648165A1 (pt)
GB (1) GB0608483D0 (pt)
MX (1) MX2008013789A (pt)
WO (1) WO2007128429A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2078728A1 (en) * 2008-01-14 2009-07-15 Université de Liège Novel isoform of versican and use in diagnosis and therapy
JP2024518180A (ja) * 2021-05-17 2024-04-25 エフ． ホフマン－ラ ロシュ アーゲー 腺筋症の非侵襲的診断のための血液バイオマーカーとしてのｓＦＲＰ４

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1159601A (en) * 1999-11-03 2001-05-14 Metris Therapeutics Limited Agents implicated in endometriosis
US20050214836A1 (en) * 2002-08-30 2005-09-29 Oncotherapy Science, Inc. Method of diagnosing ovarian endometriosis
WO2004056858A2 (en) * 2002-12-23 2004-07-08 Ingenium Pharmaceuticals Ag Methods and agents for diagnosis and prevention, amelioration or treatment of goblet cell-related disorders

Also Published As

Publication number Publication date
WO2007128429A1 (en) 2007-11-15
JP2009535023A (ja) 2009-10-01
EP2016417A1 (en) 2009-01-21
AU2007247497A1 (en) 2007-11-15
CA2648165A1 (en) 2007-11-15
CN101427139A (zh) 2009-05-06
MX2008013789A (es) 2008-11-14
GB0608483D0 (en) 2006-06-07
KR20090009212A (ko) 2009-01-22

Similar Documents

Publication Publication Date Title
BR112014007214A2 (pt) predição de evento de risco cardiovascular e utilização do mesmo
BR112012011230A2 (pt) fatores de risco e previsão de infarto do miocárdio
ATE483825T1 (de) Zusammensetzungen für die identifizierung von adenoviren
BR112013003391B8 (pt) Método para diagnosticar câncer pancreático em um indivíduo
BR112013000869A2 (pt) método para diagnóstico de câncer de próstata (pca) com uma sensibilidade desejada em um sujeito; método para monitorar a progressão do câncer de próstata (pca) em um sujeito; método para avaliar se um sujeito tem que ser submetido a uma biópsia de próstata; kit compreendendo um primeiro componente e, opcionalmente, um segundo componente e uso de um kit
BR112018073178A2 (pt) método, matriz e uso dos mesmos
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
BR112013006528A2 (pt) fosfolipidoma de câncer
IN2014DN04226A (pt)
ATE408828T1 (de) Verfahren zur erkennung eines ovarialkarzinoms
MX367366B (es) Composiciones y metodos para diagnosticar tumores de tiroides.
DE60332639D1 (de) Verwendung von biomarkern zum nachweis von eierstockkrebs
BR112012032537A2 (pt) biomarcadores de câncer de pulmão e suas utilizações
CA2697508A1 (en) Method for detecting gynecologic cancer
MX363201B (es) Procedimiento, matriz y uso para determinar la presencia de cancer pancreatico.
BRPI0515325A (pt) processo para simular os efeitos corrosivos dos estoques de provisão de refinaria sobre a metalurgia de refinaria
BRPI0614151A2 (pt) métodos para determinar quais os membros, individualmente ou em combinação, de um conjunto elementar de testes intermediários são preditivos de um conjunto elementar de resultados de teste de uso final, para prever se uma amostra candidato atenderá ao conjunto elementar de resultados de teste de uso final, para prever se uma amostra de lubrificante candidato será aprovada em um teste de uso final escolhido para lubrificantes, para determinar qual a combinação de membros de um conjunto elementar de testes intermediários que tem uma correlação elevada com um conjunto elementar de resultados de teste de uso final e para escolher componentes e quantidades de componentes em lubrificantes, fluidos funcionais ou graxas
HK1149956A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
BRPI0922052A2 (pt) Método para determinar o risco de pré-eclâmpsia usando os marcadores pigf-2 e pigf-3
BR112022019764A2 (pt) Ensaios para detecção de sars-cov-2
AR068043A1 (es) Uso de glicosaminoglicanos para reducir la union inespecifica en inmunoensayos
MX2019008911A (es) Metodos, matrices y usos de estos.
BRPI0816016B8 (pt) kit reagente para analisar uma amostra e método para analisar uma amostra
BR112015010399A2 (pt) método e kit para a determinação de cobre livre no soro
BRPI0710912A2 (pt) biomarcadores para proliferação endometrial

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 4A E 5A ANUIDADES.